Alto Neuroscience, Inc. (NYSE:ANRO) Stock Has Average Target Price of $37.25 According to Brokerages

Alto Neuroscience, Inc. (NYSE:ANRO) has received an average rating of “Moderate Buy” from the eleven research firms that are covering the firm, Marketbeat reports. One analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and eight have assigned a buy recommendation to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $37.25.

A number of research analysts recently issued reports on ANRO shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Alto Neuroscience in a research report on Wednesday, July 29th. Zacks Research raised shares of Alto Neuroscience from a “strong sell” rating to a “hold” rating in a research note on Thursday, August 20th. BTIG Research lifted their target price on shares of Alto Neuroscience from $28.00 to $37.00 and gave the company a “buy” rating in a report on Thursday, August 13th. Wall Street Zen cut Alto Neuroscience from a “hold” rating to a “sell” rating in a research report on Saturday, September 12th. Finally, Wedbush upped their price target on Alto Neuroscience from $24.00 to $26.00 and gave the stock a “neutral” rating in a research note on Thursday, August 13th.

Institutional Investors Weigh In On Alto Neuroscience

A number of institutional investors have recently modified their holdings of ANRO. GK Wealth Management LLC bought a new position in Alto Neuroscience in the 2nd quarter worth about $226,000. Revisor Wealth Management LLC bought a new position in shares of Alto Neuroscience in the first quarter worth approximately $385,000. The Manufacturers Life Insurance Company purchased a new stake in shares of Alto Neuroscience during the first quarter valued at approximately $534,000. Y Intercept Hong Kong Ltd purchased a new stake in shares of Alto Neuroscience during the first quarter valued at approximately $538,000. Finally, Bank of America Corp DE increased its position in shares of Alto Neuroscience by 131.5% during the first quarter. Bank of America Corp DE now owns 25,677 shares of the company’s stock valued at $577,000 after acquiring an additional 14,585 shares in the last quarter.

Alto Neuroscience Price Performance

Shares of ANRO stock opened at $26.67 on Tuesday. The business’s fifty day moving average is $31.20 and its 200 day moving average is $26.08. The company has a quick ratio of 14.85, a current ratio of 14.85 and a debt-to-equity ratio of 0.07. The stock has a market cap of $1.05 billion, a price-to-earnings ratio of -11.02 and a beta of 1.13. Alto Neuroscience has a twelve month low of $3.91 and a twelve month high of $37.48.

Alto Neuroscience (NYSE:ANRO) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($0.65) EPS for the quarter, beating the consensus estimate of ($0.73) by $0.08. Research analysts expect that Alto Neuroscience will post -2.68 EPS for the current fiscal year.

Alto Neuroscience Company Profile

Alto Neuroscience, Inc is a clinical-stage biopharmaceutical company focused on developing precision medicines for patients with neuropsychiatric disorders. The company combines clinical data, biological measurements and digital assessments to identify patient characteristics that may help predict treatment response and guide the development of more targeted therapies.

Alto’s pipeline has included investigational treatments for conditions such as major depressive disorder and schizophrenia.